ARGENX SE (ARGX.BR) Fundamental Analysis & Valuation

EBR:ARGX • NL0010832176

Current stock price

593.4 EUR
-6.4 (-1.07%)
Last:

This ARGX.BR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

5

1. ARGX.BR Profitability Analysis

1.1 Basic Checks

  • ARGX had positive earnings in the past year.
  • In multiple years ARGX reported negative net income over the last 5 years.
  • ARGX had a negative operating cash flow in each of the past 5 years.
ARGX.BR Yearly Net Income VS EBIT VS OCF VS FCFARGX.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M 1B

1.2 Ratios

  • ARGX's Return On Assets of 18.01% is amongst the best of the industry. ARGX outperforms 93.75% of its industry peers.
  • ARGX has a better Return On Equity (21.20%) than 92.50% of its industry peers.
  • ARGX's Return On Invested Capital of 13.04% is amongst the best of the industry. ARGX outperforms 91.25% of its industry peers.
Industry RankSector Rank
ROA 18.01%
ROE 21.2%
ROIC 13.04%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ARGX.BR Yearly ROA, ROE, ROICARGX.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 -20 -30

1.3 Margins

  • The Profit Margin of ARGX (31.12%) is better than 87.50% of its industry peers.
  • Looking at the Operating Margin, with a value of 25.68%, ARGX is in the better half of the industry, outperforming 80.00% of the companies in the same industry.
  • ARGX has a Gross Margin of 89.15%. This is in the better half of the industry: ARGX outperforms 78.75% of its industry peers.
  • In the last couple of years the Gross Margin of ARGX has remained more or less at the same level.
Industry RankSector Rank
OM 25.68%
PM (TTM) 31.12%
GM 89.15%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.34%
GM growth 5YN/A
ARGX.BR Yearly Profit, Operating, Gross MarginsARGX.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. ARGX.BR Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), ARGX is creating some value.
  • There is no outstanding debt for ARGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ARGX.BR Yearly Shares OutstandingARGX.BR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
ARGX.BR Yearly Total Debt VS Total AssetsARGX.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

  • ARGX has an Altman-Z score of 25.57. This indicates that ARGX is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 25.57, ARGX belongs to the top of the industry, outperforming 98.75% of the companies in the same industry.
  • A Debt/Equity ratio of 0.01 indicates that ARGX is not too dependend on debt financing.
  • With an excellent Debt to Equity ratio value of 0.01, ARGX belongs to the best of the industry, outperforming 90.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 25.57
ROIC/WACC1.75
WACC7.43%
ARGX.BR Yearly LT Debt VS Equity VS FCFARGX.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B

2.3 Liquidity

  • A Current Ratio of 5.60 indicates that ARGX has no problem at all paying its short term obligations.
  • ARGX has a Current ratio of 5.60. This is amongst the best in the industry. ARGX outperforms 86.25% of its industry peers.
  • A Quick Ratio of 5.27 indicates that ARGX has no problem at all paying its short term obligations.
  • With an excellent Quick ratio value of 5.27, ARGX belongs to the best of the industry, outperforming 87.50% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.6
Quick Ratio 5.27
ARGX.BR Yearly Current Assets VS Current LiabilitesARGX.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. ARGX.BR Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 1028.32% over the past year.
  • The Revenue has grown by 89.56% in the past year. This is a very strong growth!
  • Measured over the past years, ARGX shows a very strong growth in Revenue. The Revenue has been growing by 151.52% on average per year.
EPS 1Y (TTM)1028.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%762.37%
Revenue 1Y (TTM)89.56%
Revenue growth 3Y116.21%
Revenue growth 5Y151.52%
Sales Q2Q%73.67%

3.2 Future

  • ARGX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 30.38% yearly.
  • ARGX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 20.88% yearly.
EPS Next Y42.94%
EPS Next 2Y35.43%
EPS Next 3Y35.35%
EPS Next 5Y30.38%
Revenue Next Year38.91%
Revenue Next 2Y30.38%
Revenue Next 3Y25.88%
Revenue Next 5Y20.88%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ARGX.BR Yearly Revenue VS EstimatesARGX.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B 8B 10B
ARGX.BR Yearly EPS VS EstimatesARGX.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 20 40 60 80

More info and screens

Find the best growth stocksShow best growing peers

3

4. ARGX.BR Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 34.97, which means the current valuation is very expensive for ARGX.
  • Compared to the rest of the industry, the Price/Earnings ratio of ARGX indicates a somewhat cheap valuation: ARGX is cheaper than 75.00% of the companies listed in the same industry.
  • When comparing the Price/Earnings ratio of ARGX to the average of the S&P500 Index (25.79), we can say ARGX is valued slightly more expensively.
  • Based on the Price/Forward Earnings ratio of 24.46, the valuation of ARGX can be described as rather expensive.
  • 78.75% of the companies in the same industry are more expensive than ARGX, based on the Price/Forward Earnings ratio.
  • The average S&P500 Price/Forward Earnings ratio is at 23.80. ARGX is around the same levels.
Industry RankSector Rank
PE 34.97
Fwd PE 24.46
ARGX.BR Price Earnings VS Forward Price EarningsARGX.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ARGX.BR Per share dataARGX.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60 80

4.3 Compensation for Growth

  • ARGX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as ARGX's earnings are expected to grow with 35.35% in the coming years.
PEG (NY)0.81
PEG (5Y)N/A
EPS Next 2Y35.43%
EPS Next 3Y35.35%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ARGX.BR Dividend Analysis

5.1 Amount

  • ARGX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ARGX.BR Fundamentals: All Metrics, Ratios and Statistics

ARGENX SE

EBR:ARGX (3/19/2026, 3:42:20 PM)

593.4

-6.4 (-1.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)05-07
Inst Owners44.15%
Inst Owner ChangeN/A
Ins Owners0.12%
Ins Owner ChangeN/A
Market Cap36.72B
Revenue(TTM)4.15B
Net Income(TTM)1.29B
Analysts84
Price Target878.44 (48.04%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.65%
Min EPS beat(2)18.63%
Max EPS beat(2)28.67%
EPS beat(4)4
Avg EPS beat(4)19.4%
Min EPS beat(4)7.11%
Max EPS beat(4)28.67%
EPS beat(8)6
Avg EPS beat(8)2001.9%
EPS beat(12)9
Avg EPS beat(12)1341.88%
EPS beat(16)12
Avg EPS beat(16)1013.46%
Revenue beat(2)2
Avg Revenue beat(2)3.6%
Min Revenue beat(2)0.3%
Max Revenue beat(2)6.9%
Revenue beat(4)3
Avg Revenue beat(4)3.64%
Min Revenue beat(4)-0.81%
Max Revenue beat(4)8.17%
Revenue beat(8)6
Avg Revenue beat(8)4.53%
Revenue beat(12)10
Avg Revenue beat(12)6.24%
Revenue beat(16)14
Avg Revenue beat(16)21.62%
PT rev (1m)0.17%
PT rev (3m)3.83%
EPS NQ rev (1m)-11.39%
EPS NQ rev (3m)-12.04%
EPS NY rev (1m)-6.94%
EPS NY rev (3m)-4.19%
Revenue NQ rev (1m)1.81%
Revenue NQ rev (3m)1.73%
Revenue NY rev (1m)1.54%
Revenue NY rev (3m)2.06%
Valuation
Industry RankSector Rank
PE 34.97
Fwd PE 24.46
P/S 10.17
P/FCF N/A
P/OCF N/A
P/B 6.93
P/tB 7.19
EV/EBITDA N/A
EPS(TTM)16.97
EY2.86%
EPS(NY)24.26
Fwd EY4.09%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS58.34
BVpS85.66
TBVpS82.58
PEG (NY)0.81
PEG (5Y)N/A
Graham Number180.85
Profitability
Industry RankSector Rank
ROA 18.01%
ROE 21.2%
ROCE 17.38%
ROIC 13.04%
ROICexc 36.26%
ROICexgc 40.25%
OM 25.68%
PM (TTM) 31.12%
GM 89.15%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.34%
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.58
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.6
Quick Ratio 5.27
Altman-Z 25.57
F-ScoreN/A
WACC7.43%
ROIC/WACC1.75
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1028.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%762.37%
EPS Next Y42.94%
EPS Next 2Y35.43%
EPS Next 3Y35.35%
EPS Next 5Y30.38%
Revenue 1Y (TTM)89.56%
Revenue growth 3Y116.21%
Revenue growth 5Y151.52%
Sales Q2Q%73.67%
Revenue Next Year38.91%
Revenue Next 2Y30.38%
Revenue Next 3Y25.88%
Revenue Next 5Y20.88%
EBIT growth 1Y7710.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year77.31%
EBIT Next 3Y46.52%
EBIT Next 5Y34.92%
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

ARGENX SE / ARGX.BR Fundamental Analysis FAQ

What is the fundamental rating for ARGX stock?

ChartMill assigns a fundamental rating of 6 / 10 to ARGX.BR.


What is the valuation status for ARGX stock?

ChartMill assigns a valuation rating of 3 / 10 to ARGENX SE (ARGX.BR). This can be considered as Overvalued.


Can you provide the profitability details for ARGENX SE?

ARGENX SE (ARGX.BR) has a profitability rating of 5 / 10.


What are the PE and PB ratios of ARGENX SE (ARGX.BR) stock?

The Price/Earnings (PE) ratio for ARGENX SE (ARGX.BR) is 34.97 and the Price/Book (PB) ratio is 6.93.


What is the earnings growth outlook for ARGENX SE?

The Earnings per Share (EPS) of ARGENX SE (ARGX.BR) is expected to grow by 42.94% in the next year.